Abstract | BACKGROUND: METHODS: RESULTS: Eight RCTs, involving 2 883 patients, were included in our meta-analysis. Ertapenem was associated with similar clinical treatment success with ceftriaxone for complicated infections (1 326 patients, fixed-effect model, OR: 1.13, 95% CI: 0.75-1.71). There was no difference between the compared treatment groups with regard to the microbiological treatment success, and no difference was found with regard to the incidence of clinical and laboratory drug-related adverse events between ertapenem and ceftriaxone groups. As to local tolerability, overall, there was no difference between the compared groups; however, in the subgroup analysis, local reaction was significantly less in the ertapenem subgroup than the ceftriaxone plus ceftriaxone subgroup. CONCLUSIONS:
|
Authors | Nan Bai, Chunguang Sun, Jin Wang, Yun Cai, Beibei Liang, Lei Zhang, Youning Liu, Rui Wang |
Journal | Chinese medical journal
(Chin Med J (Engl))
Vol. 127
Issue 6
Pg. 1118-25
( 2014)
ISSN: 2542-5641 [Electronic] China |
PMID | 24622445
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- beta-Lactams
- Ceftriaxone
- Ertapenem
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Ceftriaxone
(therapeutic use)
- Ertapenem
- Humans
- Intraabdominal Infections
(drug therapy)
- Pneumonia
(drug therapy)
- Randomized Controlled Trials as Topic
- Urinary Tract Infections
(drug therapy)
- beta-Lactams
(therapeutic use)
|